LOGC LogicBio Therapeutics Inc.

5.76
+0.02  (+0%)
Previous Close 5.74
Open 5.77
52 Week Low 3.05
52 Week High 11.5966
Market Cap $182,810,137
Shares 31,737,871
Float 21,038,625
Enterprise Value $158,612,592
Volume 42,688
Av. Daily Volume 212,269
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
LB-001 - SUNRISE
Methylmalonic Acidemia (MMA)
Phase 1/2
Phase 1/2
Phase 1/2 enrollment to commence early 2021.

Latest News

  1. LEXINGTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the closing of its previously announced underwritten public offering of 8,050,000 shares of common stock at a price to the public of $6.00 per share, which includes the exercise in full of the underwriters' option to purchase additional shares of common stock. The gross proceeds to LogicBio from the offering were $48.3 million, before deducting underwriting discounts and commissions and offering expenses payable by LogicBio.

    Jefferies, Barclays and William Blair acted as joint book-running managers, and Chardan acted…

    LEXINGTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the closing of its previously announced underwritten public offering of 8,050,000 shares of common stock at a price to the public of $6.00 per share, which includes the exercise in full of the underwriters' option to purchase additional shares of common stock. The gross proceeds to LogicBio from the offering were $48.3 million, before deducting underwriting discounts and commissions and offering expenses payable by LogicBio.

    Jefferies, Barclays and William Blair acted as joint book-running managers, and Chardan acted as lead manager for the offering.

    LogicBio intends to use the net proceeds from the offering to support clinical development of LB-001, to progress the development of its GeneRide and Next Generation Capsid platforms, to expand its pipeline of product candidates into other indications that may be targeted by its platforms and the balance to fund working capital, capital expenditures and other general corporate purposes.

    The shares of common stock described above were offered by LogicBio pursuant to an effective shelf registration statement on Form S-3 (File No. 333-234735), which was declared effective by the Securities and Exchange Commission (SEC) on November 25, 2019. A preliminary prospectus supplement related to the offering was filed with the SEC on September 30, 2020. The final prospectus supplement related to the offering was filed with the SEC on October 2, 2020 and copies of the final prospectus supplement and the accompanying prospectus may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, NY 10022, by telephone: (877) 821-7388, or by email: , Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (888) 603-5847, or email: , or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by email at or by telephone at 1-800-621-0687. Electronic copies of the final prospectus supplement and the accompanying prospectus are also available on the website of the SEC at www.sec.gov.

    This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

    About LogicBio Therapeutics

    LogicBio Therapeutics is dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms. LogicBio's proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies. LogicBio is developing these highly potent vectors for internal development candidates and potentially for business development collaborations. LogicBio is headquartered in Lexington, Mass.

    Forward-Looking Statements

    Certain statements contained in this press release, including those relating to the expected use of proceeds from the offering, are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with general economic conditions, including as a result of the ongoing COVID-19 pandemic, and other risks identified from time to time in the reports we file with the SEC, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and the preliminary prospectus supplement and accompanying prospectus related to the offering on file with the SEC, which are available at www.sec.gov. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

    Contact:

    Matthias Jaffe

    Chief Financial Officer



    (617) 245-0399

    Primary Logo

    View Full Article Hide Full Article
  2. LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the pricing of its previously announced underwritten public offering of 7,000,000 shares of common stock at a price to the public of $6.00 per share. Gross proceeds to LogicBio from the offering are expected to be $42.0 million, before deducting underwriting discounts and commissions and offering expenses payable by LogicBio. In addition, LogicBio has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock, at the public offering price less underwriting discounts and…

    LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the pricing of its previously announced underwritten public offering of 7,000,000 shares of common stock at a price to the public of $6.00 per share. Gross proceeds to LogicBio from the offering are expected to be $42.0 million, before deducting underwriting discounts and commissions and offering expenses payable by LogicBio. In addition, LogicBio has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock, at the public offering price less underwriting discounts and commissions. All shares are being sold by LogicBio. The offering is expected to close on October 5, 2020, subject to the satisfaction of customary closing conditions.

    Jefferies, Barclays and William Blair are acting as joint book-running managers, and Chardan is acting as lead manager for the offering.

    LogicBio intends to use the net proceeds from the offering to support clinical development of LB-001, to progress the development of its GeneRide and Next Generation Capsid platforms, to expand its pipeline of product candidates into other indications that may be targeted by its platforms and the balance to fund working capital, capital expenditures and other general corporate purposes.

    The shares of common stock described above are being offered by LogicBio pursuant to an effective shelf registration statement on Form S-3 (File No. 333-234735), which was declared effective by the Securities and Exchange Commission (SEC) on November 25, 2019. A preliminary prospectus supplement related to the offering was filed with the SEC on September 30, 2020. The final prospectus supplement related to the offering will be filed with the SEC. When available, you may obtain copies of the final prospectus supplement and the accompanying prospectus from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, NY 10022, by telephone: (877) 821-7388, or by email: , Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (888) 603-5847, or email: , or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by email at or by telephone at 1-800-621-0687. Electronic copies of the final prospectus supplement and the accompanying prospectus will also be available on the website of the SEC at www.sec.gov.

    This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

    About LogicBio Therapeutics

    LogicBio Therapeutics is dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms. LogicBio's proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies. LogicBio is developing these highly potent vectors for internal development candidates and potentially for business development collaborations. LogicBio is headquartered in Lexington, Mass.

    Forward-Looking Statements

    Certain statements contained in this press release, including those relating to the expected proceeds from the offering, the use of proceeds from the offering and the expected closing of the offering, are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with the consummation of the proposed offering and general economic conditions, including as a result of the ongoing COVID-19 pandemic, and other risks identified from time to time in the reports we file with the SEC, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and the preliminary prospectus supplement and accompanying prospectus related to the offering on file with the SEC, which are available at www.sec.gov. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

    Contact:

    Matthias Jaffe

    Chief Financial Officer



    (617) 245-0399

    Primary Logo

    View Full Article Hide Full Article
  3. LEXINGTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. As part of the offering, LogicBio intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All shares being offered are to be sold by LogicBio.

    Jefferies, Barclays and William Blair are acting as joint book-running managers, and Chardan is acting as lead manager for the offering. The offering is…

    LEXINGTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. As part of the offering, LogicBio intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All shares being offered are to be sold by LogicBio.

    Jefferies, Barclays and William Blair are acting as joint book-running managers, and Chardan is acting as lead manager for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

    LogicBio intends to use the net proceeds from the offering to support clinical development of LB-001, to progress the development of its GeneRide and Next Generation Capsid platforms, to expand its pipeline of product candidates into other indications that may be targeted by its platforms and the balance to fund working capital, capital expenditures and other general corporate purposes.

    The shares of common stock described above will be offered by LogicBio pursuant to an effective shelf registration statement on Form S-3 (File No. 333-234735), which was declared effective by the Securities and Exchange Commission (SEC) on November 25, 2019. The offering will be made only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement relating to and describing the terms of the offering is expected to be filed with the SEC and, if and when filed, copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, NY 10022, by telephone: (877) 821-7388, or by email: , Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (888) 603-5847, or email: , or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by email at or by telephone at 1-800-621-0687. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at www.sec.gov.

    This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

    About LogicBio Therapeutics

    LogicBio Therapeutics is dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms. LogicBio's proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies. LogicBio is developing these highly potent vectors for internal development candidates and potentially for business development collaborations. LogicBio is headquartered in Lexington, Mass.

    Forward-Looking Statements

    Certain statements contained in this press release, including those relating to the terms of the offering and expected use of proceeds from the sale of common stock, are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with the consummation of the proposed offering and general economic conditions, including as a result of the ongoing COVID-19 pandemic, and other risks identified from time to time in the reports we file with the SEC, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and the preliminary prospectus supplement and accompanying prospectus related to the offering to be filed with the SEC, which are available at www.sec.gov. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

    Contact:

    Matthias Jaffe

    Chief Financial Officer



    (617) 245-0399

    Primary Logo

    View Full Article Hide Full Article
  4. LEXINGTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced CEO Fred Chereau will present at the Chardan Virtual Genetic Medicines Conference on Monday, October 5, 2020 at 11 AM, ET.

    A live audio webcast of the presentation will be available under the "Events and Presentations" section of LogicBio's website. A replay of the presentation will become available approximately one hour after the event and will be archived for 30 days.

    About LogicBio Therapeutics

    LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in pediatric…

    LEXINGTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced CEO Fred Chereau will present at the Chardan Virtual Genetic Medicines Conference on Monday, October 5, 2020 at 11 AM, ET.

    A live audio webcast of the presentation will be available under the "Events and Presentations" section of LogicBio's website. A replay of the presentation will become available approximately one hour after the event and will be archived for 30 days.

    About LogicBio Therapeutics

    LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients with significant unmet medical needs using GeneRide™, its proprietary technology platform. GeneRide enables the site-specific integration of a therapeutic transgene in a nuclease-free and promoterless approach by relying on the native process of homologous recombination to drive potential lifelong expression. Headquartered in Lexington, Mass., LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families. For more information, please visit www.logicbio.com

    Contacts:

    Investors:

    Matthew Lane

    Gilmartin Investor Relation

    Media:

    Stephanie Simon

    Ten Bridge Communications

    617-581-9333

    Primary Logo

    View Full Article Hide Full Article
  5. – LogicBio's First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform

    Enrollment to Start with Patients as Young as 3 Years Old, De-escalating Down to 6 Months old –

    – Webcast and Conference Call Today at 8 a.m. ET to Discuss LB-001 Update –

    LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the clinical trial design for the planned Phase 1/2 clinical trial for LB-001 in pediatric patients with methylmalonic acidemia (MMA) .

    "We're pleased to announce our plans for developing LB-001 in pediatric…

    – LogicBio's First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform

    Enrollment to Start with Patients as Young as 3 Years Old, De-escalating Down to 6 Months old –

    – Webcast and Conference Call Today at 8 a.m. ET to Discuss LB-001 Update –

    LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the clinical trial design for the planned Phase 1/2 clinical trial for LB-001 in pediatric patients with methylmalonic acidemia (MMA) .

    "We're pleased to announce our plans for developing LB-001 in pediatric patients with MMA. This is an important milestone for patients, their families, our company and for the genetic medicines space more broadly as we believe this is the first Investigational New Drug application (IND) clearance for an in vivo gene editing program harnessing homologous recombination," said Fred Chereau, CEO of LogicBio. "We have maintained a steadfast commitment to execution and the IND clearance is the first of several near-term milestones we expect to reach in our determined efforts to leverage cutting-edge medicines to address high unmet medical needs. I look forward to sharing those updates as we advance our LB-001 program."

    Daniel Gruskin, M.D., SVP, head of clinical development, commented, "The effects of MMA usually appear shortly after birth and can quickly become severe and life-threatening. Early intervention in this vulnerable population is critical to combat the manifestation of irreversible clinical disease pathologies including neurological damage. That's the reason MMA is on the newborn screening panel in the United States. Our protocol allows for the first cohort to enroll patients as young as three years old and, once certain safety parameters are met, we can age de-escalate to as young as six months old. Our goal is to provide a safe and durable therapeutic with a single administration at an age when we can make a difference for these patients."

    SUNRISE - Phase 1/2 Clinical Trial of LB-001 in Pediatric Methylmalonic Acidemia (MMA)

    The SUNRISE trial is a multi-center, open-label, Phase 1/2 clinical trial designed to assess the safety and tolerability of a single intravenous infusion of LB-001 in pediatric patients with MMA characterized by methylmalonyl-CoA mutase gene (MMUT) mutations. Six leading centers in the United States are expected to participate in the SUNRISE Phase 1/2 trial. The trial is expected to enroll eight pediatric patients with ages ranging from 6 months to 12 years, initially starting with 3 to 12 year-old patients and then adding patients aged 6 months to 2 years. The SUNRISE Phase 1/2 trial will evaluate two doses of LB-001. Patients will participate in a pre-dosing observational period and will be administered a prophylactic steroid regimen. The primary endpoint of the SUNRISE trial is to assess the safety and tolerability of LB-001 at 52 weeks after a single infusion. Additional endpoints include changes in disease-related biomarkers, including serum methylmalonic acid, clinical outcomes such as growth and healthcare utilization, and the pharmacodynamic marker albumin-2A. The Company expects to enroll the first patient in early 2021.

    LB-001 Webcast and Conference Call Information

    LogicBio will host a webcast and conference call on Monday, August 10, 2020 at 8:00 a.m. ET. The webcast will feature an overview of recently generated preclinical data using LB-001 and the planned clinical development plan for LB-001.

    The event will be broadcast live and available under the investor relations section of LogicBio's website at https://investor.logicbio.com/. The dial-in details for the call are +1 833-519-1335 or +1 602-585-9978, Conference ID: 1151546. A replay of the webcast will be available on the LogicBio website for one month following the call.

    About LogicBio Therapeutics

    LogicBio Therapeutics is dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms.

    LogicBio's proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. LogicBio has received FDA clearance for the first-in-human clinical trial of LB-001, a wholly owned genome editing program leveraging GeneRide for the treatment of methylmalonic acidemia. Patient enrollment is expected to begin in early 2021. In addition, LogicBio has a collaboration with Takeda to research and develop LB-301, an investigational therapy leveraging GeneRide for the treatment of the rare pediatric disease Crigler-Najjar syndrome.

    LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies. Data presented have shown that the capsids deliver highly efficient functional transduction of human hepatocytes with improved manufacturability with low levels of pre-existing neutralizing antibodies in human samples. Top-tier capsid candidates from this effort demonstrated significant improvements over benchmark AAVs currently in clinical development. LogicBio is developing these highly potent vectors for internal development candidates and potentially for business development collaborations.

    LogicBio is headquartered in Lexington, Mass. For more information, please visit www.logicbio.com.

    Forward Looking Statements

    This press release contains "forward-looking" statements within the meaning of the federal securities laws, including those related to the Company's plans to initiate, advance and complete its planned SUNRISE Phase 1/2 clinical trial of LB-001 in MMA; the timing, progress and results of the Company's research and development activities, including those related to the GeneRide technology platform and Next Generation Capsid Program; and its plans for LB-301 in Crigler-Najjar. These are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available. They are subject to risks and uncertainties that could cause the actual results and the implementation of the Company's plans to vary materially, including the risks associated with the initiation, cost, timing, progress and results of the Company's current and future research and development activities and preclinical studies and potential future clinical trials. In particular, the impact of the COVID-19 pandemic on the Company's ability to progress with its research, development, manufacturing and regulatory efforts, including the Company's plans to initiate, advance and complete its Phase 1/2 clinical trial for LB-001 in MMA, and the value of and market for the Company's common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. These risks are discussed in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including, without limitation, the Company's Annual Report on Form 10-K filed on March 16, 2020 with the SEC, the Company's Quarterly Report on Form 10-Q filed on May 11, 2020, and the Company's subsequent Quarterly Reports on Form 10-Q and other filings with the SEC. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

    Contacts:

    Investors:

    Brian Luque

    Associate Director, Investor Relations



    951-206-1200

    Media:

    Stephanie Simon

    Ten Bridge Communications



    617-581-9333

    Primary Logo

    View Full Article Hide Full Article
View All LogicBio Therapeutics Inc. News